RENOQUID
LOE Approachingsulfacytine
NDAORALTABLETPriority Review
Approved
Sep 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENOQUID (sulfacytine) is an oral sulfonamide antibiotic tablet approved in 1975 for urinary tract infections and related indications. Sulfacytine is a short-acting sulfonamide that works by inhibiting bacterial folate synthesis. It is primarily used in patients with uncomplicated UTIs who require oral antimicrobial therapy.
LOE Approaching
Product is in declining phase with moderate competitive pressure (30), indicating limited growth opportunities and likely consolidating commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RENOQUID currently has zero linked job openings, reflecting its mature/declining lifecycle stage and consolidating commercial footprint. Career opportunities are limited to defensive portfolio management and sales execution rather than growth or innovation roles.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.